Tafasitamab plus rituximab for PTLD after solid organ transplant
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial studies tafasitamab plus rituximab to treat a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD) in adults after a solid organ transplant. It’s aimed at helping stop the PTLD when it can be measured and before you’ve had PTLD treatment beyond limited measures like steroid or reducing anti-rejection drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent (and allow your health information to be used).
- Have PTLD that started after a solid organ transplant (heart, lung, liver, kidney, pancreas, or small intestine).
- Your PTLD tumor must be confirmed by biopsy/resection and is a B-cell type that has CD19 and CD20, with or without an EBV (virus) link.
- Have measurable disease (a tumor larger than 1.5 cm) and/or involvement in bone marrow.
- No prior PTLD treatment with chemotherapy or other cancer drugs (radiation, steroids, antivirals, and reducing anti-rejection medicines are allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doing your own stem cell transplant, followed by polatuzumab, can improve outcomes in people with specific B-cell non-Hodgkin or Hodgkin lymphomas that did not fully respond or has come back. It aims to add a targeted medicine after transplant to help control the lymphoma.
This trial tests a combination of two immunotherapy drugs (loncastuximab tesirine and rituximab) to treat a type of lymphoma (blood cancer) that develops after solid organ transplantation. The goal is to see if this treatment can help control the cancer while being safe for transplant patients.
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
This study tests a combination of two targeted antibody therapies for people newly diagnosed with follicular lymphoma. It aims to see if this combination is effective and safe for controlling the disease.
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
This trial tests a combination of three drugs (tafasitamab, lenalidomide, and rituximab) for people with newly diagnosed follicular or marginal zone lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
Hear when a new Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.